瑞波西汀联合小剂量利培酮治疗难治性抑郁症对照研究  

Reboxetine combined with small dose risperidone in the treat-ment of treatment-resistant depression

作　　者：仇红杰 赵献民 王俊成 

机构地区：[1]南乐县精神病医院,河南·南乐457400

出　　处：《临床心身疾病杂志》2014年第3期36-38,共3页Journal of Clinical Psychosomatic Diseases

摘　　要：目的：探讨瑞波西汀联合小剂量利培酮治疗难治性抑郁症的临床效果和安全性。方法将56例难治性抑郁症患者随机分为两组，每组28例，均口服瑞波西汀治疗，研究组联合小剂量利培酮治疗，观察12周。采用汉密顿抑郁量表、汉密顿焦虑量表评定临床疗效，副反应量表评定不良反应。结果治疗12周末，研究组有效率为60．7％，对照组为32．1％，研究组显著高于对照组（χ2＝4．59，P＜0．05）。研究组不良反应发生率为39．3％，对照组为32．1％，两组比较差异无显著性（χ2＝0．31，P＞0．05）。结论瑞波西汀联合小剂量利培酮治疗难治性抑郁症具有增效作用，且起效快，疗效显著，安全性高，优于单用瑞波西汀治疗。Objective To explore the efficacy and safety of reboxetine combined with small dose risperi-done in the treatment of treatment-resistant depression .Methods Fifty-six patients with treatment-resist-ant depression （TRD） were randomly assigned into two groups of 28 ones each ,both groups took orally reboxetine ,and research group was plus small dose risperidone for 12 weeks .Clinical efficacies were as-sessed with the Hamilton Depressive Scale （HAMD） and the Hamilton Anxiety Scale （HAMA） and ad-verse reactions with the Treatment Emergent Symptom Sale （TESS） .Results At the end of the 12th week effective rate was significantly higher in research than in control group （60 .7% vs .32 .1% ,χ2 =4 .59 , P〈0 .05） .The incidence of adverse reactions was 39 .3% in research and 32 .1% in control group ,which showed no significant difference （χ2 =0 .31 ,P〉0 .05） .Conclusion Reboxetine combined with small dose risperidone has a synergistic action ,takes effect more rapidly ,and has an evident effect and higher safety compared with single-use reboxetine in the treatment of treatment-resistant depression .

关 键 词：难治性抑郁症 瑞波西汀 利培酮 联合治疗 汉密顿抑郁量表 汉密顿焦虑量表 副反应量表 

分 类 号：R749.4[医药卫生—神经病学与精神病学]